Across TCGA pan-cancer cohorts, GTF2IRD2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GTF2IRD2 data layer compared with 29 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher GTF2IRD2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated GTF2IRD2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

HNSC, CCRCC, and LSCC are the cancer types where GTF2IRD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	1.000	0.749	.004	44	view →
CCRCC	DFS	Median	All	1.000	0.765	.002	19	view →
LSCC	DFS	Median	II,III,IV	0.829	1.000	.022	5	view →
LUAD	OS	Median	II,III,IV	0.439	0.927	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: GTF2IRD2 tumor-vs-normal RNA expression · all GTF2IRD2 data types